154 related articles for article (PubMed ID: 30133998)
21. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
[TBL] [Abstract][Full Text] [Related]
22. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
Puig L; Augustin M; Blauvelt A; Gottlieb AB; Vender R; Korman NJ; Thaçi D; Zhao Y; Gilloteau I; Sherif B; Williams N; Guana A; Lebwohl MG
J Am Acad Dermatol; 2018 Apr; 78(4):741-748. PubMed ID: 29066271
[TBL] [Abstract][Full Text] [Related]
23. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
[TBL] [Abstract][Full Text] [Related]
24. Erythrodermic psoriasis and secukinumab: Our clinical experience.
Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
[No Abstract] [Full Text] [Related]
25. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
[TBL] [Abstract][Full Text] [Related]
26. [Infliximab].
Goujon C; Bachelez H
Ann Dermatol Venereol; 2011 Dec; 138(12):839-41. PubMed ID: 22137623
[No Abstract] [Full Text] [Related]
27. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.
Ohtsuki M; Morita A; Igarashi A; Imafuku S; Tada Y; Fujita H; Fujishige A; Yamaguchi M; Teshima R; Tani Y; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1105-1111. PubMed ID: 28543617
[TBL] [Abstract][Full Text] [Related]
29. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
[TBL] [Abstract][Full Text] [Related]
30. Brodalumab (Siliq
Gupta AK; Versteeg SV; Abramovits W; Vincent KD
Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
[No Abstract] [Full Text] [Related]
31. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
[TBL] [Abstract][Full Text] [Related]
32. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
[TBL] [Abstract][Full Text] [Related]
33. Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report.
Odorici G; Losi A; Ciardo S; Pellacani G; Conti A
Skin Res Technol; 2018 Feb; 24(1):160-162. PubMed ID: 29067742
[No Abstract] [Full Text] [Related]
34. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
35. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.
Ho PH; Tsai TF
J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584
[TBL] [Abstract][Full Text] [Related]
37. Experience with biologics for psoriasis in daily practice: switching is worth a try.
Lecluse LL; de Groot M; Bos JD; Spuls PI
Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
[No Abstract] [Full Text] [Related]
38. Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case series.
Anzengruber F; Drach M; Maul JT; Kolios AG; Meier B; Navarini AA
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e274-e276. PubMed ID: 29356172
[No Abstract] [Full Text] [Related]
39. Secukinumab for psoriasis in a patient with hepatitis B.
Feaster B; Cline A; Feldman SR
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]